Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

458 - Real-world evidence of the safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) from Taiwan: A subgroup analysis from the prospective, observational CORRELATE study


24 Nov 2018


Poster display - Cocktail


Tumour Site

Colon and Rectal Cancer


Kun-Huei Yeh


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


K. Yeh1, T. Yang2, T. Hsu3, W.T. Chen4, H. Chen5, H. Teng6, B. Lin7, F. Kuan8, F. Chiang9, C. Duann10, Y. Li10, S. Fiala-Buskies11, M. Ducreux12, J. Wang13

Author affiliations

  • 1 Department Of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, 10002 - Taipei/TW
  • 2 Division Of Hematology/oncology, Department Of Internal Medicine, Chang Gung Memorial Hospital, Linkuo, Taipei/TW
  • 3 Department Of Colon And Rectal Surgery, Mackay Memorial Hospital, Taipei/TW
  • 4 Department Of Surgery, China Medical University Hospital, Taichung/TW
  • 5 Department Of Colorectal Surgery, Chang Gung Memorial Hospital, Kaohsiung/TW
  • 6 Division Of Medical Oncology, Department Of Oncology, Taipei Veterans General Hospital, Taipei/TW
  • 7 Division Of Colon & Rectal Surgery, National Cheng Kung University Hospital, Tainan/TW
  • 8 Department Of Hematology And Oncology, Chang Gung Memorial Hospital, Chiayi/TW
  • 9 Division Of Colon & Rectal Surgery, Taichung Veterans General Hospital, Taichung/TW
  • 10 Medical Department, Bayer Taiwan, Taipei/TW
  • 11 Development, Integrated Analysis, Bayer AG, Wuppertal/DE
  • 12 Gastrointestinal Oncology Unit, Gustave Roussy Cancer Campus Grand Paris, Villejuif/FR
  • 13 Division Of Colorectal Surgery, Department Of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City/TW


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 458


Regorafenib (160 mg daily 3 weeks on/1 week off) is approved for the treatment of patients with mCRC refractory to standard therapies. Global results from the prospective, observational CORRELATE study, which assessed 1037 patients from Europe, Asia, and Latin America in the real-world setting, showed that treatment-emergent adverse events (TEAEs) and outcomes were generally consistent with results of phase 3 trials. We present a subgroup analysis of patients enrolled from Taiwan in CORRELATE.


CORRELATE included patients with mCRC who were previously treated with approved therapies according to the local health authority approved label. The primary endpoint was the incidence of TEAEs (NCI-CTCAE v4.03). Overall survival (OS) and progression-free survival (PFS) were secondary endpoints.


A total of 128 patients from Taiwan received treatment. At study entry, most patients were ECOG performance status 0–1 (90%), 67% had KRAS mutations and 27% did not, 90% had prior anti-VEGF treatment, 42% had prior anti-EGFR, and the most common metastatic sites were liver (60%) and lung (59%). Regorafenib 160 mg/day was the initial daily dose in 28% of patients and the final dose in 15% (Table). Overall, 38% of patients had no treatment modifications, 39% had dose reductions, and 50% had an interruption/delay. TEAEs of any grade and grade ≥3 occurred in 89% and 52% of patients, respectively, and were considered regorafenib related in 64% and 23%, respectively. Grade 5 TEAEs occurred in 14% of patients of which none were considered regorafenib related. Median OS was 11.6 months and median PFS was 2.1 months.

Table: 109P

Taiwan cohort N = 128
Median age, years (range)64 (36–89)
Sex, male %66
Median BMI, kg/m223.1
Median treatment duration, months (range)2.3 (0.2–20.6)
Initial daily dose, % 160 mg/120 mg/80 mg28/48/23
Final daily dose, % 160 mg/120 mg/80 mg15/43/38
TEAEs*, % (all grade/grade ≥3) Any Hand–foot skin reaction Fatigue Anorexia Diarrhea89/52 36/10 28/2 23/2 22/4
Median OS, months (95% CI)11.6 (8.4, 13.8)
Median PFS, months (95% CI)2.1 (1.8, 2.7)

Irrespective of relation to study drug


In patients from Taiwan enrolled in CORRELATE, AEs were generally consistent with the known safety profile of regorafenib in Asian patients with mCRC. OS in this subgroup was longer than in phase 3 trials.

Editorial acknowledgement

Editorial assistance in the preparation of this abstract was provided by Katrin Gudmundsdottir of SuccinctChoice Medical Communications (London, UK), with financial support from Bayer.

Clinical trial identification


Legal entity responsible for the study





K-H. Yeh: Advisory board honorarium: Novartis, Boehringer Ingelheim, Bayer, Takeda, Bristol-Myers Squibb, Ono Pharmaceutical, Merck Serono, Merck Sharp & Dohme, Lilly, Amgen. C-W. Duann, Y-S. Li: Full time employment: Bayer. S. Fiala-Buskies: Full time employment, stock shareholder: Bayer. M. Ducreux: Grants/research support: Roche, Merck Serono; Advisory board membership: Roche, Merck Serono, Celgene, Bayer, Servier, Amgen, Ipsen; Honoraria: Bayer, Roche, Merck Serono, Servier, Amgen, Novartis, Ipsen, Lilly; Travel, accommodations, expenses: Roche, Ipsen, Merck Serono, Merck Sharp & Dohme, Lilly, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.